Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
HBM HEALTHCARE INVESTMENTS AG Financials HBM Healthcare Investments AG
Equities
HBMN
CH0012627250
Investment Management & Fund Operators
|
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 170 CHF | -2.30% | -2.86% | -15.42% | |
| Dec. 01 | AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion | MT |
| Nov. 21 | Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation | MT |
Valuation
| Fiscal Period : Maart | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1 159 | 1 320 | 2 313 | 1 920 | 1 489 | 1 182 | - | - |
| Enterprise Value (EV) 1 | 1 159 | 1 320 | 2 409 | 2 064 | 1 632 | 1 150 | 1 129 | 1 107 |
| P/E ratio | - | 7,24x | 3,06x | -24,6x | -10,2x | -16,4x | 70,2x | 11,6x |
| Yield | 4,44% | 4,05% | 3,76% | 3,51% | 3,50% | 4,41% | 3,31% | 3,31% |
| Capitalization / Revenue | - | - | - | -51,2x | -12,8x | -27,9x | 25,6x | 9,02x |
| EV / Revenue | - | - | - | -55,0x | -14,0x | -27,1x | 24,5x | 8,45x |
| EV / EBITDA | - | 7,13x | 3,18x | -27,4x | -11,2x | -16,3x | 62,7x | 10,7x |
| EV / FCF | - | -20,6x | 43,2x | -34,3x | 18,3x | 605x | 18,2x | 17,9x |
| FCF Yield | - | -4,86% | 2,31% | -2,92% | 5,46% | 0,17% | 5,48% | 5,59% |
| Price to Book | 0,89x | 1,01x | 1,08x | 0,97x | 0,84x | 0,72x | 0,73x | 0,70x |
| Nbr of stocks (in thousands) | 6 865 | 6 947 | 6 957 | 6 957 | 6 957 | 6 953 | - | - |
| Reference price 2 | 169 | 190 | 333 | 276 | 214 | 170 | 170 | 170 |
| Announcement Date | 5/16/19 | 5/8/20 | 5/27/21 | 5/18/22 | 5/26/23 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period : March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | -37,5 | -117 | -42,4 | 46,1 | 131 |
| EBITDA 1 | - | 185 | 759 | -75,3 | -146 | -70,4 | 18,0 | 103 |
| EBIT 1 | - | 185 | 759 | -75,3 | -146 | -70,4 | 18,0 | 103 |
| Operating Margin | - | - | - | 201% | 125% | 166% | 39,0% | 78,6% |
| Earnings before Tax (EBT) 1 | - | 183 | 756 | -78,0 | -145 | -71,7 | 18,0 | 103 |
| Net income 1 | - | 183 | 756 | -78,0 | -145 | -71,7 | 18,0 | 103 |
| Net margin | - | - | - | 208% | 125% | 169% | 39,0% | 78,6% |
| EPS 2 | - | 26,3 | 109 | -11,2 | -21,0 | -10,4 | 2,42 | 14,7 |
| Free Cash Flow 1 | - | -64,2 | 55,8 | -60,2 | 89,1 | 1,90 | 61,9 | 61,9 |
| FCF margin | - | - | - | 161% | -76,5% | -4,48% | 134% | 47,3% |
| FCF Conversion (EBITDA) | - | - | 7,35% | - | - | - | 344% | 60,1% |
| FCF Conversion (Net income) | - | - | 7,37% | - | - | - | 344% | 60,1% |
| Dividend per Share 2 | 7,50 | 7,70 | 12,5 | 9,70 | 7,50 | 7,50 | 5,62 | 5,62 |
| Announcement Date | 5/16/19 | 5/8/20 | 5/27/21 | 5/18/22 | 5/26/23 | - | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period : March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 96,2 | 144 | 143 | - | - | - |
| Net Cash position 1 | - | - | - | - | - | 32,0 | 53,0 | 75,0 |
| Leverage (Debt/EBITDA) | - | - | 0,13x | -1,91x | -0,98x | - | - | - |
| Free Cash Flow 1 | - | -64,2 | 55,8 | -60,2 | 89,1 | 1,90 | 61,9 | 61,9 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -4,40% | 1,00% | 6,10% |
| Shareholders' equity 1 | - | - | - | - | - | 1 630 | 1 800 | 1 689 |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 189 | 188 | 309 | 286 | 255 | 237 | 234 | 243 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 5/16/19 | 5/8/20 | 5/27/21 | 5/18/22 | 5/26/23 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating :
Investor Rating :
ESG Refinitiv :
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
170CHF
Average target price
236CHF
Spread / Average Target
+38.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.42% | 1 342 M $ | |
| -37.60% | 9 147 M $ | |
| +16.94% | 2 308 M $ | |
| -23.98% | 1 289 M $ | |
| +12.41% | 595 M $ | |
| +110.05% | 556 M $ | |
| -29.02% | 543 M $ | |
| +4.13% | 459 M $ | |
| +89.07% | 420 M $ | |
| +36.24% | 382 M $ |
- Stock
- Equities
- Stock HBM Healthcare Investments AG - Swiss Exchange
- Financials HBM Healthcare Investments AG
